Menzies Research Institute, University of Tasmania, Private bag 23, Hobart, Tasmania, 7001, Australia.
Osteoporos Int. 2011 Jan;22(1):351-5. doi: 10.1007/s00198-010-1180-y. Epub 2010 Feb 27.
The association between hormonal contraceptive use and bone mineral density remains controversial.
Hormonal contraceptive use is positively associated with bone mass in young premenopausal women.
Cross-sectional analysis of data collected from women aged 26-36 years (n = 687) in the Childhood Determinants of Adult Health study-a longitudinal study investigating childhood determinants of cardiovascular disease, diabetes, and other chronic diseases in adulthood. Participants were not currently pregnant or breast-feeding. Contraceptive use was obtained by self-administered questionnaire. Women were categorized as combined oral contraceptive users (n = 219), progestogen-only contraceptive users (n = 43), and non-users of hormonal contraceptives (n = 425). Bone mass was measured by quantitative ultrasound.
Compared with women who were not using any hormonal contraceptives, women using combined oral contraceptives had significantly higher values of broadband ultrasound attenuation (BUA), speed of sound, and quantitative ultrasound index. These associations remained after adjustment for confounders. Progestogen-only contraceptive users had higher BUA than non-users, but the differences were not statistically significant in this small group.
Combined oral contraceptive use was associated with higher bone mass measured by quantitative ultrasound in this population-based sample of premenopausal women aged 26-36 while progestogen-only contraceptives appeared to have no deleterious effect on bone mass.
激素避孕与骨密度之间的关联仍存在争议。
激素避孕药的使用与年轻绝经前妇女的骨量呈正相关。
对参加“儿童时期决定成人健康研究”的年龄在 26-36 岁的妇女(n=687)进行横断面数据分析。这是一项旨在研究儿童时期的决定因素对成人心血管疾病、糖尿病和其他慢性病的纵向研究。参与者当前未怀孕或哺乳。避孕药的使用情况通过自我管理的问卷获得。将女性分为复方口服避孕药使用者(n=219)、单纯孕激素避孕药使用者(n=43)和不使用激素避孕药的女性(n=425)。骨量通过定量超声进行测量。
与不使用任何激素避孕药的女性相比,使用复方口服避孕药的女性的宽带超声衰减(BUA)、声速和定量超声指数值明显更高。在调整了混杂因素后,这些关联仍然存在。单纯孕激素避孕药使用者的 BUA 高于非使用者,但在这个小群体中,差异无统计学意义。
在这个基于人群的 26-36 岁绝经前女性样本中,与不使用任何激素避孕药的女性相比,使用复方口服避孕药与更高的骨量相关,而单纯孕激素避孕药似乎对骨量没有不良影响。